This financing removes near-term dilution risk and extends runway through commercialization. The Phase 2 data readout and Blackstone's endorsement are strong catalysts. Monitor the 8:00 a.m. ET webcast for APEX Part B efficacy/safety details and any updates on Phase 3 timeline.
APGE drugs
APGE drug pipeline →How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 27 $77.75entry
- T+1 · 6mo ago +0.09%α −0.46% · $77.82
- T+5 · 6mo ago +1.23%α +0.03% · $78.71
- T+20 · 5mo ago +70.65%α +72.55% · $132.68
- T+60 · 3mo ago +73.31%α +71.43% · $134.75
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Apogee Therapeutics announced a strategic financing collaboration with Blackstone Life Sciences for up to $1.3 billion in non-dilutive capital, including up to $800 million in synthetic royalty funding and up to $500 million in senior corporate debt. Combined with its existing $1.3 billion cash, this positions Apogee to fund Phase 3 development and potential commercialization of zumilokibart without future equity financing. The deal is the largest royalty financing for a pre-Phase 3 program and was announced alongside APEX Phase 2 Part B data.
Key Financial Metrics
Key Facts
- Up to $1.3 billion in non-dilutive capital from Blackstone Life Sciences, including up to $800 million synthetic royalty and up to $500 million senior corporate debt.
- First $400 million preapproval funding: $100M at signing, $100M upon Phase 3 enrollment completion, $200M upon positive Phase 3 data.
- Up to $400 million additional funding available upon FDA approval, $150M at Apogee's option.
- Royalty term of 15 years on worldwide annual sales of zumilokibart, with no royalties on global annual sales exceeding $8 billion.
- Company removing its cash runway end date guidance, citing self-sustainable financial profile through commercialization without future equity financing.
- Apogee currently has $1.3 billion in total cash.
- Goldman Sachs served as exclusive financial advisor to Apogee.
Financial Impact
Up to $1.3 billion in non-dilutive capital, with $100 million received at signing. Combined with existing $1.3 billion cash, total pro-forma liquidity exceeds $2.6 billion.
Risk Factors
- Phase 3 data may not meet expectations, jeopardizing milestone payments and approval.
- Royalty obligation reduces future revenue per dollar of sales.
- Senior debt (up to $500M) adds leverage if drawn.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3301723 |
Track record
31 reports on APGE
8 of 10 bullish or bearish reports moved the stock their way by T+20. Best: +73.31% at T+60 after the May 27, 2026 report. 11 of 12 went positive at some point.
Filters
- Sep 14, 20269w ago 15-12G Neutral 4/10 No price data
- Sep 3, 202610w ago 25-NSE Bullish 8/10 Entry $135.06 No price data
- Sep 3, 202610w ago 8-K Bullish 8/10 Entry $135.06 No price data
- Aug 11, 202613w ago 8-K Bullish 7/10 Entry $134.55 No price data
- Aug 10, 202614w ago 8-K Bullish 8/10 No price data
- Aug 10, 202614w ago Press Release Bullish 8/10 Entry $134.65 No price data
- Aug 6, 202614w ago Institutional Cluster Mixed 5/10 Entry $134.49 to $135.07 ▲ +0.43% −0.17% vs SPY
- Aug 3, 202615w ago DEFA14A Bullish 5/10 Entry $134.19 to $135.08 ▲ +0.66% +1.90% vs SPY
- Jul 10, 202618w ago Insider Cluster Neutral 2/10 Entry $133.82 to $134.65 ▲ +0.62% −2.56% vs SPY
- Jun 26, 202620w ago DEFA14A Bullish 6/10 Entry $132.61 to $134.28 ▲ +1.26% +1.54% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers